部份中文香菇多糖处方资料（仅供参考）
中文名称:香菇多糖
英文名称:Lentinan
英文别名:Bromoduline; DRG-0171; LC-33; beta-D-glucopyranosyl-(1->6)-[beta-D-glucopyranosyl-(1->3)-[beta-D-glucopyranosyl-(1->6)]-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)-beta-D-glucopyranosyl-(1->3)]-beta-D-glucopyranose
药理作用
具有免疫增强作用，其机制在体内虽无直接杀伤肿瘤细胞作用，但可通过增强机体的免疫功能而发挥抗肿瘤活性。在体内能使脾脏和腹腔的NK细胞活性增强，诱生干扰素与本品剂量相关，其活性与白细胞介素类或干扰素诱导剂有协同作用。另有证明，在体外本品可增强脱氧胸腺嘧啶核苷的抗艾滋病毒的活性。
本品与抗肿瘤药合用，可起到增敏作用，尤其与FT-207并用时，其-实验动物生存期较单用FT-207组都明显延长。
药动学
本品体内药动学与葡聚糖等多糖体类似，给正常小鼠、大鼠和狗用药后，不久血中浓度迅速降低，然后缓慢下降，呈双相型变化，5分钟后主要分布于肝、脾、肺、肾等处，连续给药与单次给药体内分布相同，主要由尿排泄。
适应症
1.抗肿瘤与放疗、化疗、手术配合，主要用于不宜手术或复发的胃肠道肿瘤。本品加放疗、化疗治疗小细胞肺癌、乳癌、恶性淋巴瘤等。也可用于癌性胸腹水的治疗。
2.抗病毒可用于乙型肝炎及艾滋病等。
3.抗感染应用于具有抗药性的肺结核，也用于治疗老年性慢性支气管炎。
注：以上中文资料仅供参考，使用以原处方为准：
http://www.info.pmda.go.jp/go/pack/4299401D1083_2_04/
On April 16, Ajinomoto Pharmaceutical and Taiho Pharmaceutical Co., Ltd.
approved the manufacture and marketing approval of Ajinomoto Pharmaceutical, and with regard to anticancer agent "lentinan IV for intravenous injection 1 mg" Ajinomoto "(generic name: lentinan), which was outsourced to Taiho Pharmaceutical, From 1 July announced that Ajinomoto had agreed to sell. This sales company change is due to the expiration of the contract term.
It is a polymeric glucan extracted by hot water extraction from shiitake mushrooms, and has an action to enhance immune function.
Since its launch in 1986, "efficacy effect" is defined as "prolonging survival time by combined use with tegafur oral administration in inoperable or recurrent gastric cancer patients".